A meta-analysis of the associations between the Q141K and Q126X ABCG2 gene variants and gout risk

Background: Gout is an inflammatory disease in which genetic factors play a role. ABCG2 is a urate transporter, and the Q141K and Q126X variants of ABCG2 have been associated with a risk of developing gout, though previous studies of these associations have been inconsistent. Therefore, we conducted a meta-analysis to explore the relationship between these genetic variants and gout. Methods: We examined 8 electronic literature databases. In total, 9 eligible articles on the associations between the Q141K (rs2231142) and Q126X (rs72552713) variants and gout risk, including 11 case-control studies were selected. We used odds ratios (OR) and 95% confidence intervals (CI) to assess the strength of these relationships in dominant, recessive, and co-dominant models. Results: This study included 6652 participants (2499 gout patients and 4153 controls). The Q141K variant was found to significantly increase the risk of gout in Asians (dominant model: OR=2.64, 95% CI=2.04-3.43, P=0.02 for heterogeneity; recessive model: OR=3.19, 95% CI=2.56-3.97, P=0.28 for heterogeneity; co-dominant model: OR=1.37, 95% CI=1.18-1.59, P=0.09 for heterogeneity) and other populations (dominant model: OR=1.85, 95% CI=1.20-2.85, P<0.0001 for heterogeneity; recessive model: OR=3.78, 95% CI=2.28-6.27, P=0.19 for heterogeneity; co-dominant model: OR=1.48, 95% CI=1.26-1.74, P=0.19 for heterogeneity). The Q126X variant also significantly increased the risk of gout in Asians (dominant model: OR=3.87, 95% CI=2.07-7.24, P=0.06 for heterogeneity). Conclusions: These results suggest associations between the rs2231142 and rs72552713 ABCG2 gene polymorphisms and gout risk, which led to unfavorable outcomes. However, studies with larger sample sizes and homogeneous populations should be performed to confirm these results.     

高尿酸血症及痛风性关节炎动物模型及其中药复方治疗概况

痛风是嘌呤代谢紊乱和/或尿酸排泄减少而致血尿酸水平升高,尿酸盐(monosodium urate,MSU)晶体沉积于组织或器官并引起组织损伤的一组临床综合征,主要表现为反复发作性关节红、肿、热、痛与功能障碍,甚至关节畸形、肾石病及尿酸性肾病。高尿酸血症是痛风发生的生化基础。流行病学显示痛风的发病率在世界范围内呈逐年上升趋势。高尿酸血症/痛风严重危害人类健康,对于其发生发展机制的研究以及相关药物治疗的研究越来越受到科研工作者的重视。因此,对于高尿酸血症、痛风性关节炎动物模型的研究以及中药复方制剂在高尿酸血症/痛风中疗效的研究正如雨后春笋般如火如荼,它将从高尿酸血症、痛风性关节炎动物模型的研究及中药复方制剂在高尿酸血症/痛风中疗效的研究现状及概况做一综述。     

中国山东沿海地区汉族男性人群白介素-23受体基因多态性与痛风的易感性研究

目的探讨中国山东省沿海地区汉族男性群体的白细胞介素23受体（IL-23R）基因rs7517847位点G／T的多态性是否与痛风的易感性有关。方法选取202例痛风患者和346例健康对照者,检测中国汉族男性群体的IL-23受体内含子区rs7517847位点基因多态性分布,数据经,检验得出其与痛风发病的遗传易感性的关系。结果经,检验,痛风组和对照组中IL-23R基因rs7517847位点GG,GT和1Tr基因型频率（10．4％,49．5％,40．1％;16．2％,49．7％,34．1％;X^2=4．305,P〉0．05）与等位基因频率G和T（35．1％,41％;64．9％,59％;X^2=3．727,P〉0．05）均无统计学意义。IL-23R基因rs7517847位点G／T基因多态性与痛风病的危险因素无显著性关联。结论尚不能认为中国沿海地区汉族男性人群中IL-23R内含子区rs7517847位点基因多态性与痛风有关联性。     

Prevention of Comorbidity and Acute Attack of Gout by Uric Acid Lowering Therapy

The object of this study was to evaluate the effect of uric acid lowering therapy in reducing the new development of comorbidities and the frequency of acute attacks in gout patients. We retrospectively reviewed patients who were diagnosed to have gout with at least 3 yr of follow up. They were divided into 2 groups; 53 patients with mean serum uric acid level (sUA)<6 mg/dL and 147 patients with mean sUA≥6 mg/dL. Comorbidities of gout such as hypertension (HTN), type II diabetes mellitus (DM), chronic kidney disease, cardiovascular disease (CVD) and urolithiasis were compared in each group at baseline and at last follow-up visit. Frequency of acute gout attacks were also compared between the groups. During the mean follow up period of 7.6 yr, the yearly rate of acute attack and the new development of HTN, DM, CVD and urolithiasis was lower in the adequately treated group compared to the inadequately treated group. Tight control of uric acid decreases the incidence of acute gout attacks and comorbidities of gout such as HTN, DM, CVD and urolithiasis.

Graphical Abstract

相似文献   

葡萄糖转运体9基因 rs3733591（C>T）的单核苷酸多态性与我国汉族人群原发性痛风发病的相关性研究

目的探讨葡萄糖转运体9（SLC2A9）基因 rs3733591（C>T）的单核苷酸多态性（SNPs）与我国汉族人群痛风发病及血尿酸水平的相关性,并分析其多态性与痛风患者、健康体检者 PBMCs SLC2A9 mRNA 表达的相关性。方法①采用 TaqMan?探针法检测痛风组（297例原发性痛风性关节炎患者）和健康对照组（211名健康体检者） rs3733591（C>T）位点的基因型,χ2检验比较2组基因型及等位基因分布频率,计算比值比（OR）及95%可信区间（95%CI）。②采用实时荧光定量-PCR（RT-qPCR）法检测46例间歇期痛风患者及40名健康对照组 PBMCs SLC2A9 mRNA 的表达水平,非参数检验比较各组变量间的差异,并分析与 rs3733591（C>T）多态性的相关性。结果 rs3733591（C>T）位点的 TT 基因型在痛风组的分布频率显著低于健康对照组（37.7%与48.3%,P=0.017）,携带 TT 基因型的个体罹患痛风的相对风险OR 为0.647（95%CI：0.452~0.925）。而等位基因 T 在痛风组中的分布频率为60.9%,显著低于健康对照组的69.2%（χ2=7.324,P=0.007）,携带等位基因 T 的个体罹患痛风的相对风险 OR 为0.695（95%CI：0.533~0.905）;等位基因 C 在痛风组中的分布频率为39.1%,显著高于健康对照组的30.8%（χ2=1.440,P<0.05）。痛风组中携带 TC 基因型个体的外周血单个核细胞 SLC2A9 mRNA 的表达水平显著高于携带 TT 基因型者,而痛风组及健康对照组携带其他基因型的个体 SLC2A9 mRNA 的表达差异无统计学意义（P>0.05）。有痛风石（30例）痛风患者与无痛风石（190例）痛风患者的基因型及等位基因分布频率差异无统计学意义（P>0.05）。结论本研究提示 SLC2A9基因 rs3733591（C>T）位点的多态性可能与我国汉族人群原发性痛风的易感性相关,而与痛风患者痛风石形成无关;等位基因 C 可能为痛风发病的风险因子,而 TT 基因型及 T 等位基因可能对痛风发病具有保护作用;其多态性可能通过影响 SLC2A9基因的转录表达水平来参与痛风的发病。     

Gout in African Americans

Purpose

African Americans have a substantially higher prevalence of risk factors for gout than Caucasians. The aim of the present study was to compare the risk for incident gout among African Americans and Caucasians.

Methods

Incidence rates of physician-diagnosed gout among 11,559 Caucasian men and 931 African American men aged 35 to 57 years and at high cardiovascular risk, observed for 7 years as a part of the Multiple Risk Factor Intervention Trial, were analyzed. Cox regression models were used to account for potential confounding by age, body mass index, diuretic use, hypertension and diabetes status, aspirin and alcohol consumption, and kidney disease.

Results

At baseline, after accounting for risk factors, African Americans had a 14% lower prevalence of hyperuricemia than Caucasians. Incidence of gout increased with increasing prevalence of risk factors in both Caucasians and African Americans. Ethnic disparities in incidence rates were most apparent among those without other risk factors for gout. In separate Cox regression models, after accounting for risk factors, African American ethnicity was associated with a hazard ratio of 0.78 (95% confidence interval [CI], 0.66-0.93) for physician-diagnosed gout and 0.88 (95% CI, 0.85-0.90) for incident hyperuricemia. Significant interactions were observed; the association was the strongest (hazard ratio 0.47; 0.37-0.60). These associations were unaffected by addition of serum urate as a covariate or by using alternate case definitions for gout.

Conclusions

After accounting for the higher prevalence of risk factors, African American ethnicity is associated with a significantly lower risk for gout and hyperuricemia compared with Caucasian ethnicity.     

心理应激与高尿酸血症患者血尿酸关系研究

目的探讨生活事件心理应激相关因素与高尿酸血症患者血尿酸水平之间的关系。方法采用生活事件量表对60例高尿酸血症患者精神刺激进行定性和定量研究分析,并通过实验室检测分析比较不同压力下高尿酸血症患者的一般资料及生化指标的差异,并进一步进行相关性分析和多元回归分析。结果将生活事件量表总分小于等于20分的患者纳入低压力组,总分大于20分的纳入高压力组。正性、负性生活事件出现频率最高的事件分别为突出的个人成就、晋级和提升等,以及工作学习中压力大、生活规律重大变动、对现职工作不满意等。高压力组的患者最近1年的痛风发作频率以及总胆固醇、三酰甘油、血肌酐、血尿酸、皮质醇水平显著高于低压力组(P<0.05)。生活事件总刺激量与总胆固醇、三酰甘油、血肌酐和血尿酸呈正相关,其中正性生活事件刺激量与总胆固醇和三酰甘油呈正相关,负性生活事件刺激量和尿酸呈正相关。以血尿酸为因变量的多元线性回归分析中,最近1年痛风发作频率和压力分组最终进入回归模型,该回归模型具有统计学意义F(2,54)=27.765(P<0.01),调整R^2=0.522。结论在生活事件中的家庭生活和工作上受到的刺激较大的高尿酸血症患者,精神心理压力与机体总胆固醇、三酰甘油、血尿酸水平升高有关,其中三酰甘油和总胆固醇的升高与正性生活事件有关,而血尿酸的升高则是与负性生活事件有一定关系。高尿酸血症的患者,其较高的压力水平和频发的痛风与血尿酸升高有关。     

一种新型尿酸氧化酶四聚体提取纯化方法的建立

目的 建立一种简便、快速的尿酸氧化酶四聚体提取纯化的方法,以适应大规模生产需求。方法 首先通过基因工程的方法获得可以稳定发酵生产尿酸氧化酶的大肠埃希菌菌株,再通过一步萃取法从破碎菌体沉淀中获得尿酸氧化酶蛋白混合物,通过硫酸铵沉淀、离子交换和分子筛层析,最终获得纯化的活性尿酸氧化酶四聚体。结果 通过优化发酵及提取条件,每升发酵液可得到尿酸氧化酶四聚体蛋白约400 mg,其纯度>95%,比活>10 U/mg。结论 建立了一种新的尿酸氧化酶四聚体高效提取纯化的方法。     

Serum urate levels are unchanged with continuous positive airway pressure therapy for obstructive sleep apnea: a randomized controlled trial

ObjectiveHyperuricemia is associated with the presence and severity of obstructive sleep apnea (OSA). Previous work has shown that treatment of OSA with continuous positive airway pressure (CPAP) therapy reduces urinary uric acid excretion and serum urate, but there has been no previous randomized controlled investigation on the effects of CPAP therapy on serum urate; we aimed to assess this association.MethodsSerum urate was measured in samples from participants of a previously published randomized controlled trial. Samples were taken at baseline and after 3 months from men with known type 2 diabetes mellitus (T2DM) and newly diagnosed OSA, randomized to receive either therapeutic (n = 19) or placebo (n = 19) CPAP for 3 months.ResultsBoth groups were well matched at baseline, with no significant difference in age, body mass index (BMI), glycosylated hemoglobin (HbA1c), or oxygen desaturation index (ODI). There was no significant difference in therapeutic or placebo CPAP usage. There was no significant difference in urate levels between groups at baseline (362 μmol/L [standard deviation {SD}, 96] vs 413 μmol/L [SD, 91] [reference range, 110–428 μmol/L]) or at 3 months. Baseline urate did not correlate with ODI, BMI, or HbA1c. The mean change in urate at 3 months did not significantly differ between treatment groups (−7.6 μmol/L [SD, 35.9] vs −6.2 μmol/L [SD, 46.2]) (P = .9; [95% confidence interval, −28.7 to +25.9]).ConclusionOur randomized controlled trial has shown no significant reduction in serum urate following 3 months treatment with therapeutic or placebo CPAP.